Eyepoint Pharmaceuticals, Inc. $EYPT Shares Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. raised its holdings in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 314.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 375,264 shares of the company’s stock after purchasing an additional 284,824 shares during the period. Eyepoint Pharmaceuticals comprises 0.1% of Simplify Asset Management Inc.’s holdings, making the stock its 28th largest position. Simplify Asset Management Inc. owned about 0.45% of Eyepoint Pharmaceuticals worth $6,856,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of EYPT. State of Alaska Department of Revenue acquired a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at $50,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after purchasing an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Eyepoint Pharmaceuticals in the 3rd quarter valued at $76,000. Tower Research Capital LLC TRC raised its stake in Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after purchasing an additional 5,967 shares during the last quarter. Finally, Raymond James Financial Inc. raised its stake in Eyepoint Pharmaceuticals by 11.0% in the 2nd quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock valued at $112,000 after purchasing an additional 1,177 shares during the last quarter. 99.41% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.46% of the company’s stock.

Eyepoint Pharmaceuticals Stock Performance

NASDAQ EYPT opened at $12.93 on Monday. The stock’s fifty day moving average is $13.46 and its two-hundred day moving average is $14.68. The firm has a market capitalization of $1.08 billion, a P/E ratio of -3.69 and a beta of 1.76. Eyepoint Pharmaceuticals, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.35 million. Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%. As a group, sell-side analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -3.16 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on EYPT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Royal Bank Of Canada reduced their price objective on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Citigroup increased their price objective on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, March 9th. HC Wainwright increased their price objective on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Finally, Chardan Capital boosted their price objective on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Eyepoint Pharmaceuticals has an average rating of “Buy” and a consensus target price of $31.80.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.